Expansion Therapeutics is a company working to find a cure for Myotonic dystrophy type 1 also called DM 1. To aid in their search for a cure, Expansion Therapeutics is working to obtain financing. 5AM Ventures, which is headed by Scott Rocklage, is one of the major venture capital firms contributing to Expansion Therapeutics’ efforts. 5AM Ventures, working alongside several other groups, has helped raise over $55 million to help Expansion Therapeutics with its DM 1 research.
DM 1 occurs when RNA molecules are converted into proteins. The RNA levels in some people can reach a state where the muscles and the internal organs are seriously affected. DM 1 is a congenital condition, and it has been known to affect many members of the same family line.
Scott Rocklage has helped to bring a research team on board to aid Expansion Therapeutics in its quest to cure DM 1. Leading the research team will be Dr. Matthew D. Disney. He has been working on a cure for DM 1 for over the past 12 years.
Through his investment firm 5AM Ventures, Scott Rocklage is able to provide investment capital and management assistance to those working in various areas of medical research. Dr. Rocklage has provided the leadership needed to bring three drugs from the testing phase through FDA approval.
In addition to his work at 5AM Ventures, Dr. Rocklage has served as both chairman and CEO of Cubist Pharmaceuticals. He was also executive chairman of Semprus and Miikana. Scott Rocklage holds 30 patents for products for which he either invented or helped to invent.
Connect with Dr. Scott Rocklage on LinkedIn.